Finance Watch: VCs Are Sharing The Wealth With More Biopharmas

Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.

Finance Watch

Venture capital investment in biopharmaceutical firms dropped from a record high of $18.6bn in 2018 to $16.6bn in 2019 – the second-highest amount of VC cash raised by the industry in a single year – but it was the number of companies receiving venture investment that broke a record – 866 in 2019 versus 831 in 2018. What that means is that while venture investors continue to back a lot of $100m-plus mega-rounds, they also put more money into smaller VC rounds for earlier-stage companies.

Digging a little deeper into the Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) released in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.